FOLH1 and prostate carcinoma: Disease progression is often assessed at the patient level, and numerous patient-level criteria have been developed for assessing radiographic progression, including: the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the PET Evaluation Response Criteria in Solid Tumors (PERCIST), the updated Prostate Cancer Working Group 3 (PCWG3) criteria, and, more recently, PSMA PET-specific response criteria such as the PSMA PET Progression Criteria (PPP) and the Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0)11–15.